


## PROTAC CDK12/13 Degradator-1

Cat. No.:	HY-151110
Molecular Formula:	C <sub>45</sub> H <sub>46</sub> N <sub>10</sub> O <sub>6</sub>
Molecular Weight:	822.91
Target:	CDK; PROTACs
Pathway:	Cell Cycle/DNA Damage; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PROTAC CDK12/13 Degradator-1 (7f) is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC <sub>50</sub> values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degradator-1 has anti-proliferative activity and can be used in breast cancer research <sup>[1]</sup> .																			
<b>IC<sub>50</sub> &amp; Target</b>	CDK12 2.2 nM (DC <sub>50</sub> )	CDK13 2.1 nM (DC <sub>50</sub> )																		
<b>In Vitro</b>	<p>PROTAC CDK12/13 Degradator-1 (7f) (0.02-10 μM, 150 h) significantly inhibits the proliferation of MFM223 and MDA-MB-231 cells in a dose-dependent manner<sup>[1]</sup>.</p> <p>PROTAC CDK12/13 Degradator-1 (7f) (500 nM, 4 h) can significantly degrade CDK12 and CDK13 of MFM223 and MDA-MB-231 cells in a dose-dependent manner<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Immunofluorescence<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td colspan="3">MDA-MB-231 cell lines</td> </tr> <tr> <td>Concentration:</td> <td colspan="3">1.0 μM</td> </tr> <tr> <td>Incubation Time:</td> <td colspan="3">15 hours</td> </tr> <tr> <td>Result:</td> <td colspan="3">           Showed 88% degradation for CDK12 and 74% for CDK13.            Acted on CDK12 with the DC<sub>50</sub> value of 2.2 nM, and acted on CDK13 with the DC<sub>50</sub> value of 2.1 nM.         </td> </tr> </table>				Cell Line:	MDA-MB-231 cell lines			Concentration:	1.0 μM			Incubation Time:	15 hours			Result:	Showed 88% degradation for CDK12 and 74% for CDK13. Acted on CDK12 with the DC <sub>50</sub> value of 2.2 nM, and acted on CDK13 with the DC <sub>50</sub> value of 2.1 nM.		
Cell Line:	MDA-MB-231 cell lines																			
Concentration:	1.0 μM																			
Incubation Time:	15 hours																			
Result:	Showed 88% degradation for CDK12 and 74% for CDK13. Acted on CDK12 with the DC <sub>50</sub> value of 2.2 nM, and acted on CDK13 with the DC <sub>50</sub> value of 2.1 nM.																			
<b>In Vivo</b>	The pharmacokinetic parameters of PROTAC CDK12/13 Degradator-1 (7f) in rats <sup>[1]</sup> .																			
	Parameters	oral (20 mg/kg)	iv (10 mg/kg)	ip (20 mg/kg)	iv (2.5 mg/kg)															
	t <sub>1/2</sub> (h)	-	5.28	10.85	5.8															
	T <sub>max</sub> (h)	5.33	0.08	2.17	0.08															

C <sub>max</sub> (ng/mL)	7.73	19892.4	24.79	1498.5
C <sub>max</sub> (ng/mL)	7.73	19892.4	24.79	1498.5
AUC <sub>0-t</sub> (h*ng/mL)	21.83	7193.3	284.8	383.9
AUC <sub>0-∞</sub> (h*ng/mL)	-	7242.7	318.5	391.55
CL (mL/h/kg)	-	1406.5	-	6495.4
F (%)	0.15	-	10.63	-

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Jianzhang Yang, et al. Discovery of a Highly Potent and Selective Dual PROTAC Degradator of CDK12 and CDK13. J Med Chem. 2022 Aug 8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA